FDA approves treatment for chronic graft versus host disease - FDA Press Releases

The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the first FDA-approved therapy for the treatment of cGVHD.

from Food and Drug Administration--Press Releases http://ift.tt/2w5XGgj
via IFTTT